Short Interest In SciClone Pharmaceuticals Drops 17.6%

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 462,133 share decrease in total short interest for SciClone Pharmaceuticals, Inc. ( SCLN), to 2,167,158, a decrease of 17.58% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for SCLN at the 10/31/2016 settlement increased to 257,570, as compared to 213,661 at the 10/14/2016 report. That brought "days to cover" down to 8.41, a 31.63% decrease from the 12.31 days to cover calculated at the previous short interest data release.

The below chart shows the historical "days to cover" for SCLN at previous short interest release dates:

Top 25 S.A.F.E. Dividend Stocks »

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where SCLN had been shorted as a hedge.

The chart below shows the one year performance of SCLN shares, versus its 200 day moving average. Looking at this chart, SCLN's low point in its 52 week range is $7.37 per share, with $15.03 as the 52 week high point — that compares with a last trade of $9.60.

If you liked this article you might like

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Today's Weak On High Volume Stock: SciClone Pharmaceuticals (SCLN)

SciClone Pharmaceuticals (SCLN): Today's Weak On High Volume Stock

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan